TIG1
|
WikiDoc Resources for TIG1 |
|
Articles |
|---|
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on TIG1 at Clinical Trials.gov Clinical Trials on TIG1 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on TIG1
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating TIG1 Risk calculators and risk factors for TIG1
|
|
Healthcare Provider Resources |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Tazarotene-induced gene-1 (TIG1) is a protein which has been implicated as a putative tumor suppressor. It is structurally similar to the protein latexin, which has also been shown to demonstrate some tumor suppression activity (Liang et al., 2007). TIG1 is thought to be a transmembrane protein, and its mechanism of tumor suppression is largely unknown.
Structure
The amino acid sequence of the protein TIG1 is as follows:
N terminus-Met-Gln-Pro-Arg-Arg-Gln-Arg-Leu-Pro- Ala-Pro-Trp-Ser-Gly-Pro-Arg-Gly-Pro-Arg-Pro-Thr- Ala-Pro-Leu-Leu-Ala-Leu-Leu-Leu-Leu-Leu-Ala-Pro- Val-Ala-Ala-Pro-Ala-Gly-Ser-Gly-Gly-Pro-Asp-Asp- Pro-Gly-Gln-Pro-Gln-Asp-Ala-Gly-Val-Pro-Arg-Arg- Leu-Leu-Gln-Gln-Lys-Ala-Arg-Ala-Ala-Leu-His-Phe- Phe-Asn-Phe-Arg-Ser-Gly-Ser-Pro-Ser-Ala-Leu-Arg- Val-Leu-Ala-Glu-Val-Gln-Glu-Gly-Arg-Ala-Trp-Ile- Asn-Pro-Lys-Glu-Gly-Cys-Lys-Val-His-Val-Val-Phe- Ser-Thr-Glu-Arg-Tyr-Asn-Pro-Glu-Ser-Leu-Leu-Gln- Glu-Gly-Glu-Gly-Arg-Leu-Gly-Lys-Cys-Ser-Ala-Arg- Val-Phe-Phe-Lys-Asn-Gln-Lys-Pro-Arg-Pro-Thr-Ile- Asn-Val-Thr-Cys-Thr-Arg-Leu-Ile-Glu-Lys-Lys-Lys -Gln-Gln-Glu-Asp-Tyr-Leu-Leu-Tyr-Lys-Gln-Met-Lys- Gln-Leu-Lys-Asn-Pro-Leu-Glu-Ile-Val-Ser-Ile-Pro- Asp-Asn-His-Gly-His-Ile-Asp-Pro-Ser-Leu-Arg-Leu- Ile-Trp-Asp-Leu-Ala-Phe-Leu-Gly-Ser-Ser-Tyr-Val- Met-Trp-Glu-Met-Thr-Thr-Gln-Val-Ser-His-Tyr-Tyr- Leu-Ala-Gln-Leu-Thr-Ser-Val-Arg-Gln-Trp-Val-Arg- Lys-Thr-CTerminus.
TIG1 is a transmembrane protein which contains a hyaluronic acid binding motif. This particular motif suggests that it may increase cell-to-cell contact in cells which express TIG1 (Jing et al., 2002). TIG1 is predicted to contain a membrane anchor at the N-terminus. TIG1 contains two faces: the first face contains homology to the protein latexin, and the second contains a broad basic patch. The basic face is thought to be an interaction surface. Supporting the idea of a protein interaction surface, TIG1 also contains a cis-peptide bond between isoleucine-122 and proline-123 on a protruding loop that lies on its basic face (Aagard et al., 2005). Latexin and TIG1 have approximately 30 percent homology based on primary structure; however, their three-dimensional structures are thought to be much more similar (Liang et al., 2007). Both latexin and TIG1 are thought to have descended from a common progenitor. TIG1 also shares homology with another protein, ovacalyxin-32, although the evolutionary and functional relationship between the two proteins is unclear (Gautron et al., 2001).
Function
TIG1's specific functions are still in the process of being elucidated. Latexin is a structurally similar protein to TIG1. Latexin is the only mammalian carboxypeptidase inhibitor, although TIG1’s proteolytic activity remains unexplored. Using a selective subtractive differential gene display, Jing and colleagues discovered that TIG1 expression was absent from malignant prostate carcinoma cell lines but present in benign tumor lines. When highly malignant prostate cancer cells were transfected with TIG1, decreased in vitro invasiveness was measured using an extracellular matrix migration assay over a period of 48 hours. This same group of scientists performed another experiment in which TIG1 expression was restored in mice that were homozygous for the deletion of the TIG1 gene. Although the restoration of TIG1 did not prevent tumor growth in these mice, the average size of the tumors showed a 2.4 fold decrease (Jing et al., 2006).
Regulation
The promoter of TIG1 is silenced by hypermethylation in gastric cancer. Promoter hypermethylation is a common mechanism for silencing tumor suppression genes. During carcinogenesis, methylation begins at the CpG island of the promoter and gradually works its way to the transcription start site, at which point it inhibits transcription of TIG1 (So et al., 2006). Additionally, the CpG promoter hypermethylation of TIG1 has also been demonstrated as an important event in the carcinogenesis of prostate adenocarcinoma (Cho et al., 2007).
References
- Aagaard et al.: “An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1.” Structure 13(2), 309-317, 2005.
- Cho et al.: "Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features." J Pathology 211(3), 269-277, 2007.
- Gautron et al.: “Ovacalyxin-32, a novel chicken eggshell matrix protein.” J Biol Chem 276(42), 39243-39252, 2001.
- Jing et al.: “Tazarotene-Induced Gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity” J Natl Cancer Institute 94(7), 482-490, 2002.
- Liang et al.: “The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice.” Nature Genetics 39(2), 178-188, 2007.
- So et al.: “Multiple tumor suppressor genes are increasingly methylated with age in non-neoplastic gastric epithelia.” Cancer Sci 97(11), 1155-1158, 2006.